Arrowhead Pharmaceuticals Statistics
Total Valuation
ARWR has a market cap or net worth of $9.52 billion. The enterprise value is $9.30 billion.
| Market Cap | 9.52B |
| Enterprise Value | 9.30B |
Important Dates
The next estimated earnings date is Monday, May 11, 2026, after market close.
| Earnings Date | May 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ARWR has 140.03 million shares outstanding. The number of shares has increased by 10.94% in one year.
| Current Share Class | 140.03M |
| Shares Outstanding | 140.03M |
| Shares Change (YoY) | +10.94% |
| Shares Change (QoQ) | +2.05% |
| Owned by Insiders (%) | 3.32% |
| Owned by Institutions (%) | 76.35% |
| Float | 122.04M |
Valuation Ratios
The trailing PE ratio is 46.08.
| PE Ratio | 46.08 |
| Forward PE | n/a |
| PS Ratio | 8.73 |
| Forward PS | 48.12 |
| PB Ratio | 16.43 |
| P/TBV Ratio | 16.94 |
| P/FCF Ratio | 29.56 |
| P/OCF Ratio | 28.06 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 28.57, with an EV/FCF ratio of 28.89.
| EV / Earnings | 45.99 |
| EV / Sales | 8.53 |
| EV / EBITDA | 28.57 |
| EV / EBIT | 30.95 |
| EV / FCF | 28.89 |
Financial Position
The company has a current ratio of 3.38, with a Debt / Equity ratio of 1.24.
| Current Ratio | 3.38 |
| Quick Ratio | 3.26 |
| Debt / Equity | 1.24 |
| Debt / EBITDA | 2.04 |
| Debt / FCF | 2.17 |
| Interest Coverage | 3.33 |
Financial Efficiency
Return on equity (ROE) is 75.50% and return on invested capital (ROIC) is 81.47%.
| Return on Equity (ROE) | 75.50% |
| Return on Assets (ROA) | 14.35% |
| Return on Invested Capital (ROIC) | 81.47% |
| Return on Capital Employed (ROCE) | 23.92% |
| Weighted Average Cost of Capital (WACC) | 11.28% |
| Revenue Per Employee | $1.53M |
| Profits Per Employee | $284,480 |
| Employee Count | 711 |
| Asset Turnover | 0.83 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ARWR has paid $21.35 million in taxes.
| Income Tax | 21.35M |
| Effective Tax Rate | 8.37% |
Stock Price Statistics
The stock price has increased by +428.21% in the last 52 weeks. The beta is 1.27, so ARWR's price volatility has been higher than the market average.
| Beta (5Y) | 1.27 |
| 52-Week Price Change | +428.21% |
| 50-Day Moving Average | 61.90 |
| 200-Day Moving Average | 45.58 |
| Relative Strength Index (RSI) | 60.86 |
| Average Volume (20 Days) | 2,048,797 |
Short Selling Information
The latest short interest is 13.00 million, so 9.29% of the outstanding shares have been sold short.
| Short Interest | 13.00M |
| Short Previous Month | 11.43M |
| Short % of Shares Out | 9.29% |
| Short % of Float | 10.66% |
| Short Ratio (days to cover) | 5.10 |
Income Statement
In the last 12 months, ARWR had revenue of $1.09 billion and earned $202.27 million in profits. Earnings per share was $1.48.
| Revenue | 1.09B |
| Gross Profit | 1.09B |
| Operating Income | 300.57M |
| Pretax Income | 254.92M |
| Net Income | 202.27M |
| EBITDA | 325.65M |
| EBIT | 300.57M |
| Earnings Per Share (EPS) | $1.48 |
Balance Sheet
The company has $914.71 million in cash and $698.16 million in debt, with a net cash position of $216.55 million or $1.55 per share.
| Cash & Cash Equivalents | 914.71M |
| Total Debt | 698.16M |
| Net Cash | 216.55M |
| Net Cash Per Share | $1.55 |
| Equity (Book Value) | 562.70M |
| Book Value Per Share | 4.14 |
| Working Capital | 826.96M |
Cash Flow
In the last 12 months, operating cash flow was $339.31 million and capital expenditures -$17.30 million, giving a free cash flow of $322.01 million.
| Operating Cash Flow | 339.31M |
| Capital Expenditures | -17.30M |
| Depreciation & Amortization | 25.08M |
| Net Borrowing | -258.05M |
| Free Cash Flow | 322.01M |
| FCF Per Share | $2.30 |
Margins
Gross margin is 100.00%, with operating and profit margins of 27.55% and 18.54%.
| Gross Margin | 100.00% |
| Operating Margin | 27.55% |
| Pretax Margin | 23.37% |
| Profit Margin | 18.54% |
| EBITDA Margin | 29.85% |
| EBIT Margin | 27.55% |
| FCF Margin | 29.52% |
Dividends & Yields
ARWR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.94% |
| Shareholder Yield | -10.94% |
| Earnings Yield | 2.12% |
| FCF Yield | 3.38% |
Analyst Forecast
The average price target for ARWR is $81.50, which is 19.89% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $81.50 |
| Price Target Difference | 19.89% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 13.16% |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on November 17, 2011. It was a reverse split with a ratio of 1:10.
| Last Split Date | Nov 17, 2011 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
ARWR has an Altman Z-Score of 2.55 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.55 |
| Piotroski F-Score | 6 |